Anne Zaremba

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 25, 2026

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.

Journal: Frontiers in immunology

Published: October 17, 2025

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 24, 2025

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2024

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.

Journal: Science advances

Published: November 27, 2024

Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.

Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 11, 2024

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 29, 2024

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 10, 2024

Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.

Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.

Journal: Frontiers in immunology

Published: February 06, 2024

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2023

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 22, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026